Roche Pharmaceutical Development and Sales Overview
YTD Sep 2022: Oncology portfolio rejuvenation on-going
YoY CER growth
Phesgo (+150%)
HER2 franchise
Herceptin
Perjeta (+5%)
+4%
•
Kadcyla (+11%)
Tecentriq
+10%
Polivy (+79%)
Hematology
Rituxan
franchise
-7%
Gazyva(+8%)
Avastin
-29%
Alecensa
+16%
Cotellic +
Cotellic (+1%)
-3%
Zelboraf
Rozlytrek +50%
Tarceva
-33%
Gavreto +299%
CHFbn 0.0
2.0
4.0
6.0
8.0
HER2 franchise
•
•
Kadcyla (+11%) with growth ex-US due to adjuvant BC
Perjeta (+5%) driven by International, especially APAC
Phesgo (CHF 526m): 30% conversion in early launch countries
Tecentriq
•
Growth (+10%) driven by adjuvant NSCLC, 1L HCC and 1L SCLC
Hematology franchise
•
Venclexta*: Expanding patient share in 1L AML & R/R CLL
.
Gazyva (+8%): Growth due to 1L FL and in 1L CLL
•
Polivy (+79%): Strong 1L DLBCL uptake in early launch countries;
PDUFA date for 1L DLBCL (POLARIX) set for Apr 2nd
Roche
•
Lunsumio: Approved in EU with strong early launch in Germany and
Austria; PDUFA set for Dec 29th
Alecensa
•
Strong growth (+16%) and 1L ALK+ NSCLC leadership in major markets
YTD Sep 2022 Oncology sales: CHF 15.0bn; CER growth -1%; CER-Constant Exchange Rates; * Venclexta sales booked by AbbVie and therefore not included; Polivy in collaboration with Seagen; BC=breast cancer;
HCC-hepatocellular carcinoma; NSCLC-non-small cell lung cancer; SCLC-small cell lung cancer; AML-acute myeloid leukemia; R/R CLL=relapsed/refractory chronic lymphocytic leukemia; FL=follicular lymphoma;
DLBCL-diffuse large B cell lymphoma; PDUFA-Prescription Drug User Fee Act; ALK-anaplastic lymphoma kinase
19View entire presentation